| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
MY-5445 manufacturers
- MY-5445
-
- $67.00
-
2026-07-24
- CAS:78351-75-4
- Purity: 99.77%
- Supply Ability: 10g
|
| | MY-5445 Basic information |
| Product Name: | MY-5445 | | Synonyms: | MY-5445;1-(3-CHLOROPHENYLAMINO)-4-PHENYLPHTHALAZINE;1-(3-CHLOROANILINO)-4-PHENYLPHTHALAZINE;N-(3-Chlorophenyl)-4-phenyl-1-phthalazinamine;N-(3-chlorophenyl)-4-phenylphthalazin-1-amine;MY 5445;MY5445;1-(3-Chloroanilino)-4-phenylphthalazine >;aggregation,platelet,Inhibitor,anticancer,inhibit,MY5445,neuropathic,MY 5445,Phosphodiesterase (PDE),neuropathic pain,allodynia,MY-5445 | | CAS: | 78351-75-4 | | MF: | C20H14ClN3 | | MW: | 331.8 | | EINECS: | | | Product Categories: | Cyclic Nucleotide related | | Mol File: | 78351-75-4.mol |  |
| | MY-5445 Chemical Properties |
| Boiling point | 539.7±50.0 °C(Predicted) | | density | 1.310±0.06 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | DMF: 2 mg/ml; DMSO: 2 mg/ml; DMSO:PBS(pH 7.2) (1:2): 0.3 mg/ml | | pka | 4.91±0.30(Predicted) | | form | Yellow solid. | | color | White to Light yellow |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26-36 | | HS Code | 2933.99.8290 |
| | MY-5445 Usage And Synthesis |
| Description | MY-5445 is a selective inhibitor of the cyclic GMP (cGMP) phosphodiesterase, PDE5, with a Ki value of 1.3 μM. It inhibits calcium- and cAMP-selective PDEs with Ki values of >1,000 and 915 μM, respectively. MY-5445 has been shown to relax intact strips of rat aorta with an EC50 value of 4 μM. | | Uses | MY-5445 is a selective cGMP phosphodiesterase inhibitor. Potent PDE5 inhibitor. | | Definition | ChEBI: N-(3-chlorophenyl)-4-phenyl-1-phthalazinamine is a ring assembly and a member of pyridazines. | | Biological Activity | Specific inhibitor of cyclic GMP phosphodiesterase, selective for PDE5 (IC 50 = 0.5 μ M). | | in vivo | MY-5445 (0.5-3 mg/kg; i.p.; twice a day; for 15 days) produces a significant relief of mechanical hypersensitivity[3].
| Animal Model: | C57BL/6J male mice[3] | | Dosage: | 0.5 mg/kg, 3 mg/kg | | Administration: | Intraperitoneal injection, twice a day, for 15 days | | Result: | Alleviated the cuff-induced allodynia. |
| | IC 50 | PDE5: 1.3 μM (Ki); PDE5: 6.7 μM (IC50); PDE4: 37 μM (IC50) | | References | [1] JOHN E. SOUNESS. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine[J]. British Journal of Pharmacology, 1989, 98 3: 725-734. DOI: 10.1111/j.1476-5381.1989.tb14599.x
[2] T YAMAMOTO. Complex effects of inhibitors on cyclic GMP-stimulated cyclic nucleotide phosphodiesterase.[J]. The Journal of Biological Chemistry, 1983, 258 23: 14173-14177.
|
| | MY-5445 Preparation Products And Raw materials |
|